Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
3.
Emerg Microbes Infect ; 10(1): 2235-2243, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34749573

ABSTRACT

As the SARS-CoV-2 pandemic continues to rage worldwide, the emergence of numerous variants of concern (VOC) represents a challenge for the vaccinal protective efficacy and the reliability of commercially available high-throughput immunoassays. Our study demonstrates the administration of two doses of the BNT162b2 vaccine that elicited a robust SARS-CoV-2-specific immune response which was assessed up to 3 months after full vaccination in a cohort of 37 health care workers (HCWs). SARS-CoV-2-specific antibody response, evaluated by four commercially available chemiluminescence immunoassays (CLIA), was qualitatively consistent with the results provided by the gold-standard in vitro neutralization assay (NTA). However, we could not observe a correlation between the quantity of the antibody detected by CLIA assays and their neutralizing activity tested by NTA. Almost all subjects developed a SARS-CoV-2-specific T-cell response. Moreover, vaccinated HCWs developed a similar protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion. These results underline the importance of a solid vaccine-elicited immune response and a robust antibody titre. We believe that these relevant results should be taken into consideration in the definition of future vaccinal strategies.


Subject(s)
BNT162 Vaccine/immunology , COVID-19 Vaccines/immunology , COVID-19/immunology , COVID-19/prevention & control , SARS-CoV-2/immunology , Adult , Aged , Antibodies, Neutralizing/blood , Antibodies, Neutralizing/immunology , Antibodies, Viral/blood , Antibodies, Viral/immunology , BNT162 Vaccine/administration & dosage , BNT162 Vaccine/genetics , COVID-19/blood , COVID-19/virology , COVID-19 Vaccines/administration & dosage , COVID-19 Vaccines/genetics , Female , Humans , Immunity, Cellular , Immunity, Humoral , Immunoassay , Longitudinal Studies , Male , Middle Aged , Prospective Studies , SARS-CoV-2/genetics , T-Lymphocytes/immunology , Vaccination , Young Adult
4.
Clin Microbiol Infect ; 24(12): 1340.e1-1340.e6, 2018 Dec.
Article in English | MEDLINE | ID: mdl-29555394

ABSTRACT

OBJECTIVES: We aimed to assess the prevalence and risk factors for Chagas disease (CD) in Latin American immigrants and to evaluate the accuracy of diagnostic tests. Moreover, we offered to all positive subjects a complete free-of-charge clinical/instrumental evaluation as well as benznidazole treatment in order to stage the disease and verify drug tolerability. METHODS: A cross-sectional survey of CD among Latin Americans living in Milan and its metropolitan area was conducted between July 2013 and July 2014. Blood samples were tested for serologic evidence of CD together with a questionnaire covering demographic and clinical-epidemiological information. RESULTS: Forty-eight (9.6%) of the 501 tested subjects were conclusively diagnosed as having CD. The highest prevalence of CD was among those from Bolivia (43/169, 25.4%) and El Salvador (4/68, 5.9%). Older age (adjusted odds ratio (aOR)] 1.05, p =0.004), a Bolivian origin (aOR 8.80; p =0.003), being born in the department of Santa Cruz (aOR 3.72, p =0.047), having lived in mud houses (aOR 2.68; p =0.019), and having an affected relative (aOR 12.77, p =0.001) were independently associated with CD. The ARCHITECT Chagas test showed the highest sensitivity (100%) and specificity (99.8%). Twenty-nine of the subjects with CD (60.4%) underwent disease staging, 10 of whom (35.7%) showed cardiac and/or digestive involvement. Benznidazole treatment was associated with high frequency of adverse reactions (19/27, 70.4%) and permanent discontinuation (8/27, 29.6%). CONCLUSIONS: CD is highly prevalent among Bolivians and Salvadorans living in Milan. Regions with a large Latin American immigrant population should implement programmes of active detection and treatment.


Subject(s)
Chagas Disease/diagnosis , Chagas Disease/epidemiology , Emigrants and Immigrants , Hispanic or Latino/statistics & numerical data , Adolescent , Adult , Bolivia/epidemiology , Chagas Disease/blood , Chagas Disease/immunology , Child , Cross-Sectional Studies , Data Accuracy , Drug Tolerance , El Salvador/epidemiology , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoassay/methods , Italy/epidemiology , Latin America/epidemiology , Male , Middle Aged , Nitroimidazoles/adverse effects , Nitroimidazoles/therapeutic use , Prevalence , Risk Factors , Surveys and Questionnaires , Trypanosoma cruzi/drug effects , Trypanosoma cruzi/immunology , Trypanosoma cruzi/isolation & purification
5.
Biochim Biophys Acta ; 1543(1): 146-58, 2000 Nov 30.
Article in English | MEDLINE | ID: mdl-11087950

ABSTRACT

Within a research project aimed at probing the substrate specificity and the enantioselectivity of Candida rugosa lipase (CRL), computer modeling studies of the interactions between CRL and methyl (+/-)-2-(3-benzoylphenyl)propionate (Ketoprofen methyl ester) have been carried out in order to identify which amino acids are essential to the enzyme/substrate interaction. Different binding models of the substrate enantiomers to the active site of CRL were investigated by applying a computational protocol based on molecular docking, conformational analysis, and energy minimization procedures. The structural models of the computer generated complexes between CRL and the substrates enabled us to propose that Phe344 and Phe345, in addition to the residues constituting the catalytic triad and the oxyanion hole, are the amino acids mainly involved in the enzyme-ligand interactions. To test the importance of these residues for the enzymatic activity, site-directed mutagenesis of the selected amino acids has been performed, and the mutated enzymes have been evaluated for their conversion and selectivity capabilities toward different substrates. The experimental results obtained in these biotransformation reactions indicate that Phe344 and especially Phe345 influence CRL activity, supporting the findings of our theoretical simulations.


Subject(s)
Candida/genetics , Lipase/genetics , Propionates/metabolism , Base Sequence , Binding Sites , Candida/enzymology , Esters/metabolism , Ketoprofen/chemistry , Lipase/metabolism , Models, Chemical , Models, Molecular , Molecular Sequence Data , Mutagenesis, Site-Directed , Naproxen/chemistry , Recombinant Proteins/genetics , Stereoisomerism , Structure-Activity Relationship , Substrate Specificity
6.
Chem Phys Lipids ; 93(1-2): 47-55, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9720249

ABSTRACT

The fungus C. rugosa produces lipase isoenzymes (CRLs) homologous to the Geotrichum candidum and Yarrowia lipolytica lipases to which they share ca. 40 and 30% sequence identity, with a domain of sequence conservation at the N-terminal half of the protein. CRL proteins have high sequence homology but are not identical in their catalytic activity, therefore calling for the resolution of isoforms via heterologous expression. The non-conventional use of a serine codon in several Candida species frustrates overexpression in the currently available host systems. The LIP1 gene, coding for the major CRL form, was therefore expressed in C. maltosa, a related fungus with the same codon usage as C. rugosa. A recombinant lipase was produced and secreted in an active form in the culture medium upon engineering the 5' and 3' ends of the gene.


Subject(s)
Candida/enzymology , Fungal Proteins/biosynthesis , Isoenzymes/biosynthesis , Lipase/biosynthesis , Candida/genetics , Codon , Fungal Proteins/genetics , Isoenzymes/genetics , Lipase/genetics , Protein Conformation
SELECTION OF CITATIONS
SEARCH DETAIL
...